10月8日消息 - Ascendis Pharma A/S宣布:
该公司已向欧洲药品管理局提交TransCon® CNP的营销授权申请,用于治疗软骨发育不全症儿童。
同时,该公司表示PDUFA目标日期已设定为2025年11月30日。
10月8日消息 - Ascendis Pharma A/S宣布:
该公司已向欧洲药品管理局提交TransCon® CNP的营销授权申请,用于治疗软骨发育不全症儿童。
同时,该公司表示PDUFA目标日期已设定为2025年11月30日。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.